Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,397 across all filing types
Latest filing 2020-03-10 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 98% confidence The document is clearly identified by the header 'RNS Number : 4907F' and the closing statement mentions 'This information is provided by RNS, the news service of the London Stock Exchange.' RNS stands for Regulatory News Service. The content details 'Transactions by Persons Discharging Managerial Responsibilities (PDMRs)' regarding the granting of share awards under incentive plans (AZDBP and AZPSP) to executives like the CEO and CFO. This type of insider transaction disclosure is a mandatory regulatory filing in many jurisdictions, often submitted via the RNS system. While it relates to director remuneration (DEF 14A) and insider trading (DIRS), the primary context and format strongly suggest a general regulatory announcement disseminated through the RNS channel, which is the most specific category for this type of official, time-sensitive regulatory disclosure that isn't a core financial report (like 10-K or IR). Given the options, RNS is the most appropriate general regulatory filing category for this specific RNS announcement.
2020-03-10 English
UPDATE ON PHASE III DANUBE TRIAL FOR IMFINZI AND TREMELIMUMAB IN UNRESECTABLE, S
Regulatory Filings
2020-03-06 English
Update on Phase III DANUBE trial in bladder cancer
Legal Proceedings Report Classification · 99% confidence The document begins with 'RNS Number : 2577F' and is dated 06 March 2020. It contains an 'Update on Phase III DANUBE trial for Imfinzi and tremelimumab in unresectable, Stage IV bladder cancer'. The text concludes with boilerplate language referencing RNS, the London Stock Exchange, and the Financial Conduct Authority, and ends with 'END'. This structure is characteristic of a regulatory news service announcement, which is a broad category for official company disclosures that do not fit a more specific filing type (like 10-K, ER, or DIV). Since it is a general regulatory announcement and not a specific report like an Earnings Release (ER) or an Interim Report (IR), the most appropriate classification is Regulatory Filings (RNS). The document length (11045 chars) is substantial, but the content is a specific clinical trial update disseminated via the RNS system, making RNS the best fit over a more specific category like LTR (Legal Proceedings Report) or ER (Earnings Release).
2020-03-06 English
FILING OF FORM 20-F WITH SEC
Regulatory Filings
2020-03-04 English
Filing of Form 20-F with SEC
Report Publication Announcement Classification · 99% confidence The document explicitly states: 'RNS Number : 9133E' and 'Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission'. It further clarifies that the company 'filed its 2019 Annual Report on Form 20-F with the US Securities and Exchange Commission (SEC)'. However, the document itself is very short (3216 chars) and its primary function is to announce the filing and provide contact details, rather than containing the full content of the 20-F (which is the Annual Report, 10-K equivalent for foreign issuers). The presence of the RNS number and the announcement structure strongly suggests this is a regulatory announcement about a report publication. Therefore, it fits the definition of Report Publication Announcement (RPA) or potentially a general Regulatory Filing (RNS). Since RPA specifically covers announcements regarding the publication of reports, it is the most precise fit, even though the underlying document is an Annual Report (Form 20-F). Given the 'MENU VS MEAL' rule, this is the announcement (the menu), not the full report (the meal).
2020-03-04 English
IRANNOTICE
Regulatory Filings
2020-03-03 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.